Business
GeoVax Announces Oncology Advisory Board to Advance Gedeptin(R) Development Across Solid Tumors
Members Bring Deep Expertise in Immuno-Oncology, Translational Medicine, and Checkpoint Inhibitor Combination Strategies ATLANTA - February 24, 2026
About this update from Geovax Labs, Inc.
[{"type":"text","content":"Members Bring Deep Expertise in Immuno-Oncology, Translational Medicine, and Checkpoint Inhibitor Combination Strategies\nATLANTA - February 24, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines for cancers and infectious diseases, today announced the formation of its Oncology Advisory Board with the appointment of three internationally recognized leaders in immuno-oncology, translational medicine, and clinical development.\nThis Advisory Board will play a central role in guiding the scientific, translational, and clinical advancement of GeoVax's oncology program, focused primarily on Gedeptin®, the company's gene-directed enzyme prodrug therapeutic (GDEPT). GeoVax plans to conduct a Phase 2 trial with Gedeptin in the neoadjuvant setting, pairing it with an immune checkpoint inhibitor (ICI) in locally advanced head and neck squamous cell carcinoma. In parallel, it will be evaluating combination Gedeptin + ICI strategies across additional solid tumor indications.\nOncology Advisory Board Members\nChas Bountra, PhD, OBEProfessor of Translational Medicine, University of OxfordFormer Pro-Vice-Chancellor for Innovation, University of OxfordFormer Vice President & Head of Biology, GlaxoSmithKline\nDr. Bountra brings extensive leadership spanning academia, biotech, and global pharmaceutical R&D. He is widely recognized for building translational drug discovery engines, advancing novel therapeutic modalities into the clinic, and creating high-impact academic-industry partnerships. His expertise in translational medicine, drug development strategy, and innovation ecosystems will support Gedeptin's progression from proof-of-concept to clinically scalable development programs aligned with regulatory and partnership pathways.\nMarc S. Ernstoff, MDDirector, Experimental Cell Therapy, Dartmouth HealthFormer Chief, Immuno-Oncology Branch, National Cancer Institute (NIH)\nDr. Ernstoff is a recognized pioneer in cancer immunotherapy with significant experience across cytokine therapy, checkpoint inhibitors, and combination immuno-oncology trials. His career includes leadership roles at the National Cancer Institute, Roswell Park Comprehensive Cancer Center, Dartmouth-Hitchcock, and Yale, with direct involvement in numerous landmark immunotherapy studies. His exp...